These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 36092658)

  • 1. Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems.
    Hejabi F; Abbaszadeh MS; Taji S; O'Neill A; Farjadian F; Doroudian M
    Front Chem; 2022; 10():957572. PubMed ID: 36092658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.
    Li L; Hu S; Chen X
    Biomaterials; 2018 Jul; 171():207-218. PubMed ID: 29704747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing.
    Duan L; Ouyang K; Xu X; Xu L; Wen C; Zhou X; Qin Z; Xu Z; Sun W; Liang Y
    Front Genet; 2021; 12():673286. PubMed ID: 34054927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active Delivery of CRISPR System Using Targetable or Controllable Nanocarriers.
    Lyu Y; Yang C; Lyu X; Pu K
    Small; 2021 Jun; 17(24):e2005222. PubMed ID: 33759340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-, Inorganic-, Polymer-, and DNA-Based Nanocarriers for Delivery of the CRISPR/Cas9 system.
    Song N; Chu Y; Tang J; Yang D
    Chembiochem; 2023 Aug; 24(16):e202300180. PubMed ID: 37183575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in stimuli-responsive polymeric carriers for controllable CRISPR/Cas9 gene editing system delivery.
    Ma P; Wang Q; Luo X; Mao L; Wang Z; Ye E; Loh XJ; Li Z; Wu YL
    Biomater Sci; 2023 Jul; 11(15):5078-5094. PubMed ID: 37282836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposome-Based Carriers for CRISPR Genome Editing.
    Yin X; Harmancey R; McPherson DD; Kim H; Huang SL
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.
    Shalaby K; Aouida M; El-Agnaf O
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress and challenges towards CRISPR/Cas clinical translation.
    Rosenblum D; Gutkin A; Dammes N; Peer D
    Adv Drug Deliv Rev; 2020; 154-155():176-186. PubMed ID: 32659256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-derived extracellular vesicles for CRISPR/Cas9 delivery: engineering strategies for cargo packaging and loading.
    Liang Y; Iqbal Z; Wang J; Xu L; Xu X; Ouyang K; Zhang H; Lu J; Duan L; Xia J
    Biomater Sci; 2022 Jul; 10(15):4095-4106. PubMed ID: 35766814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognizing CRISPR as the new age disease-modifying drug: Strategies to bioengineer CRISPR/Cas for direct in vivo delivery.
    Thevendran R; Maheswaran S
    Biotechnol J; 2023 Sep; 18(9):e2300077. PubMed ID: 37179485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
    Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
    J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy.
    Song X; Liu C; Wang N; Huang H; He S; Gong C; Wei Y
    Adv Drug Deliv Rev; 2021 Jan; 168():158-180. PubMed ID: 32360576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections.
    Verma R; Sahu R; Singh DD; Egbo TE
    Semin Cell Dev Biol; 2019 Dec; 96():44-52. PubMed ID: 30986568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges.
    Taha EA; Lee J; Hotta A
    J Control Release; 2022 Feb; 342():345-361. PubMed ID: 35026352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies.
    Banda A; Impomeni O; Singh A; Baloch AR; Hu W; Jaijyan DK
    Vaccines (Basel); 2024 Jun; 12(6):. PubMed ID: 38932365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral Vectors for the
    Asmamaw Mengstie M
    Front Bioeng Biotechnol; 2022; 10():895713. PubMed ID: 35646852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.